Biomedical Physics & Engineering Express
ACCEPTED MANUSCRIPT
Preparation of liposomes encapsulated Epirubicin-gold nanoparticles for Tumor specific delivery and release To cite this article before publication: Selvaraj Kunjiappan et al 2018 Biomed. Phys. Eng. Express in press https://doi.org/10.1088/20571976/aac9ec
Manuscript version: Accepted Manuscript Accepted Manuscript is “the version of the article accepted for publication including all changes made as a result of the peer review process, and which may also include the addition to the article by IOP Publishing of a header, an article ID, a cover sheet and/or an ‘Accepted Manuscript’ watermark, but excluding any other editing, typesetting or other changes made by IOP Publishing and/or its licensors” This Accepted Manuscript is © 2018 IOP Publishing Ltd.
During the embargo period (the 12 month period from the publication of the Version of Record of this article), the Accepted Manuscript is fully protected by copyright and cannot be reused or reposted elsewhere. As the Version of Record of this article is going to be / has been published on a subscription basis, this Accepted Manuscript is available for reuse under a CC BY-NC-ND 3.0 licence after the 12 month embargo period. After the embargo period, everyone is permitted to use copy and redistribute this article for non-commercial purposes only, provided that they adhere to all the terms of the licence https://creativecommons.org/licences/by-nc-nd/3.0 Although reasonable endeavours have been taken to obtain all necessary permissions from third parties to include their copyrighted content within this article, their full citation and copyright line may not be present in this Accepted Manuscript version. Before using any content from this article, please refer to the Version of Record on IOPscience once published for full citation and copyright details, as permissions will likely be required. All third party content is fully copyright protected, unless specifically stated otherwise in the figure caption in the Version of Record. View the article online for updates and enhancements.
This content was downloaded from IP address 130.64.11.153 on 04/06/2018 at 19:02
Page 1 of 35
Preparation of liposomes encapsulated Epirubicin-gold nanoparticles for Tumor specific
2
delivery and release
3
Selvaraj Kunjiappan1*, Theivendran Panneerselvam2, Balasubramanian Somasundaram1,
4
Sankarganesh Arunachalam1 Murugesan Sankaranarayanan3 and Pavadai Parasuraman4
us cri
5 6 7
1
8
Krishnankoil-626126, India
9
2
pt
1
Sir CV Raman-KS Krishnan International Research Center, Kalasalingam University,
an
Department of Pharmaceutical Chemistry, Karavali College of Pharmacy, Vamanjoor, Near
Reymond, Mangaluru-575028, India
11
3
Department of Pharmacy, Birla Institute of Technology and Science, Pilani-333031, India
12
4
Department of Pharmacy, M S Ramaiah University of Applied Sciences, Gnanagangothri
13
Campus, Bengaluru-560054, India.
dM
10
14 15 16
*
17
Dr. Selvaraj Kunjiappan,
18
Research Faculty,
19
Sir CV Raman-KS Krishnan International Research Center,
20
Kalasalingam University,
21
Krishnankoil-626126, India
22
Email:
[email protected]
23
Ph: +919994972108
ce
pte
Address to correspondence
Ac
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
AUTHOR SUBMITTED MANUSCRIPT - BPEX-101073.R1
1
AUTHOR SUBMITTED MANUSCRIPT - BPEX-101073.R1
Abstract
25
Liposome/metal nanoparticle conjugates are found to be a promising carrier tool for effectively
26
delivering wide variety of drugs in a targeted site and without arguing toxic side effects of
27
existing anticancer drugs. In this scenario, the present work was performed to choose Epirubicin-
28
HCl (EPI) as model anticancer drug to formulate citrate stabilized EPI-gold nanoparticles (EPI-
29
GNPs). Further, the biocompatible EPI-GNPs incorporated with lipid bilayer of liposomes
30
formulated to exhibit effective drug delivery system. The biosynthesized EPI-GNPs and its
31
incorporation in a lipid bilayer of liposomes was confirmed by UV-visible spectrophotometer,
32
drug encapsulation, loading capacity, pH stability and drug releasing capacity were studied.
33
Simultaneously, drug and carrier interaction, physical nature, stability, morphological and
34
particle size characteristics were also studied by FTIR, XRD, SEM, TEM and Zeta size analyzer.
35
The obtained characterization data confirmed the properties of EPI-GNPs encapsulated
36
liposomes. The in vitro cytotoxic screening of EPI-GNPs encapsulated liposomes arrest the
37
proliferation of MCF-7 breast cancer cell lines, at 0.1 µg/mL of liposomes displayed 52% of cell
38
death at 24 h. The EPI-GNPs encapsulated liposomes induced time and dose dependent apoptosis
39
compared with untreated control cancer cells.
42 43 44 45
us cri
an
dM
pte
41
Keywords: Epirubicin, drug delivery, liposomes, gold nanoparticles, breast cancer, cytotoxicity
ce
40
pt
24
Ac
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 2 of 35
46
2
Page 3 of 35
1. Introduction
48
Breast cancer is the most widely recognized malignancy in females and it is a leading cause for
49
death rate in women (14% of all cancer deaths) worldwide [1]. However, cancer cells proliferate
50
at much faster rate than the normal cells. Breast cancer tends to spread metastasis primarily to
51
lymph nodes, liver, lungs, bones and brain [2]. Therefore, breast cancer has become major health
52
concern and proper treatment of breast cancer has nowadays become a necessity. Recently, a
53
number of recognized chemotherapeutic agents are in market for effective breast cancer therapy,
54
but unfortunately, they have inability to selectively deliver the drugs to tumor targets, shorter life
55
time and aggressively producing undesirable toxic side effects to normal tissues [3]. Therefore,
56
there is a pressing need to develop alternative way of drug delivery system to deliver a sufficient
57
dose of drug to the disease location with less invasive but more efficient cancer treatments by the
58
currently available chemotherapeutic agents. The most promising drug delivery system would be
59
to exploit nanotechnology based biodegradable carrier material to explore the treatment of cancer
60
at its molecular level. Presently polymers, proteins, liposomes, solid lipid nanoparticles, and
61
metal nanoparticle-conjugated biodegradable systems are helpful for therapeutic purposes [4].
62
Among the above carrier systems, liposomes with metal nanoparticle conjugate have many
63
advantages in the field of drug delivery systems because of their nanosize, high surface to
64
volume ratio, less severe adverse reaction with enhanced cancer treatment [5]. Liposomes are the
65
simplest artificial biological cell, and are well known to reduce toxicity related with many
66
compounds including antitumor drugs, antiviral drugs and antibiotics [6]. Further, it is currently
67
being introduced into clinical use and several more are under clinical trials or pre-clinical
68
development [7]. Liposomes are submicronic spherical vesicular structure consisting of mono or
69
bilayer of phospholipids/cholesterol having a hydrophobic tail and a hydrophilic head, which can
ce
pte
dM
an
us cri
pt
47
Ac
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
AUTHOR SUBMITTED MANUSCRIPT - BPEX-101073.R1
3
AUTHOR SUBMITTED MANUSCRIPT - BPEX-101073.R1
be encapsulated with both hydrophilic and hydrophobic drugs depending on the preparation
71
method [8].
72
In the recent decade, gold nanoparticles (GNPs) have been remarkably being used in a wide
73
range of biomedical applications in view of their stability, nanosize, bio compatibility and have
74
displayed unique and tunable surface plasmon resonance (SPR) [9]. These points of interest
75
empower the GNPs to target tumor all the more effectively without severe accumulation in
76
reticuloendothelial system, making them exceptionally encouraging for cancer diagnosis and
77
treatment [10, 11]. Further, GNPs have demonstrated high affinities with highly selective
78
targeting properties to either tissues or cells and passively aggregate at tumor sites because of
79
upgraded permeability and retention (EPR) effects [12]. It is also flexible to surface functionalize
80
with various biomolecules such as protein, DNA, algae, enzymes, and plant-derived bioactive
81
compounds [13, 14]. Therefore, GNPs are currently the subject of exceptional research for
82
potential clinical applications.
83
The hybrid GNPs/liposomal conjugate can be prepared by GNPs encapsulation or surface
84
coating with lipids, which is a useful non-covalent approach to stabilize surface chemistry for
85
prolonged plasma circulation improving pharmacokinetic profile and reducing clearance by
86
circumventing reticuloendothelial system (RES) uptake [15]. Epirubicin-HCl (EPI) is an
87
anthracycline antineoplastic agent that acts by DNA intercalation and inhibiting topoisomerase
88
II, which further interfere with DNA, RNA and protein synthesis [16]. EPI is a 4’-epimer of
89
Doxorubicin (DOX) and differs in the orientation of the C-4 hydroxyl group on the sugar that has
90
several beneficial effects over DOX including improved efficacy, lower toxicity, rapid clearance
91
from plasma resulting in less cumulative dose, and thus can successfully replace DOX in breast
92
cancer treatment [17, 18]. But the use of free EPI is rather limited due to the severe side effects
ce
pte
dM
an
us cri
pt
70
Ac
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 4 of 35
4
Page 5 of 35
and multidrug resistance [19]. Hence, the investigation reported here is aimed to enhance the
94
therapeutic effects of EPI and reduce its toxic side effects by synthesizing GNPs and
95
encapsulating them in a lipid bilayer on nanoparticles. In the present study, a novel strategy was
96
employed to exploit the use of sodium citrate dihyrate as a reducing and stabilizing agent for the
97
biosynthesis of GNPs and subsequently attached with EPI. The stabilized EPI-GNPs were
98
encapsulated in liposomes by conventional thin film hydration method. Then, the formulated
99
GNPs/liposomal conjugate were characterized by analytical techniques to evaluate their size,
100
size-distribution, morphology, stability, encapsulation efficiency, and drug releasing capacity.
101
Further, in vitro anticancer activity was evaluated against breast cancer cell lines (MCF-7).
102
2. Materials and Methods
103
2.1. Materials
104
The chemicals, Hydrogen tetracholoroaureate (III) hydrates (HAuCl4.3H2O (99.9%)), Sodium
105
citrate dihydrate (99%), 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyltetrazolium bromide (MTT),
106
fetal bovine serum (FBS), Dichloro-dihydro-fluorescein diacetate (DCFH-DA), Dulbecco’s
107
Modified Eagles Medium (DMEM) and the solvents, analytical grade ethanol (95%), chloroform
108
(98%) and toluene (99.7%) were procured from Himedia Laboratories Pvt., Ltd., Mumbai, India.
109
Distearoyl phosphatidylcholine (DSPC) with >99% purity was obtained from Lipoid (Germany)
110
and used without further purification. Cholesterol was purchased from Sigma Aldrich Company
111
(St. Louis, USA). All other chemicals and solvents used in this study were of analytical grade
112
and obtained from Merck, Mumbai, India. Epirubicin-HCl (4′-epidoxorubicin hydrochloride;
113
(EPI)) was received as kind gift from Alkem Laboratories Ltd., Mumbai, India. Glassware were
114
washed with dilute nitric acid and thoroughly rinsed with double distilled water and dried in hot
ce
pte
dM
an
us cri
pt
93
Ac
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
AUTHOR SUBMITTED MANUSCRIPT - BPEX-101073.R1
5
AUTHOR SUBMITTED MANUSCRIPT - BPEX-101073.R1
air oven with before use. MCF-7 cell line was obtained from National Centre for Cell Science
116
(NCCS, Pune, India).
117
2.2. Synthesis of GNPs
118
Citrate-stabilized GNPs were synthesized by a modified procedure similar to that of Frens, 1973
119
[20]. In short, 10 mL of sodium citrate di hydrate (0.01 M) was added to 90 mL of aqueous
120
solution of 1 × 10−4 M HAuCl4∙3H2O and the solution was kept under magnetic stirring at 60°C
121
for 30 min. This procedure results in a ruby red solution containing monodisperse GNPs. The
122
formation of GNPs was monitored with UV-visible spectrophotometer. GNPs were obtained by
123
centrifugation at 12000 × g for 30 min and washed several times with de-ionized water by
124
centrifugation and re-dispersion in water to remove excess gold.
125
2.3. Preparation of EPI-GNPs
126
2 mg of EPI was added to GNPs dispersion, obtained as described above, resulting in a final EPI
127
concentration of 10−4 M in solution. The mixture of EPI and GNPs dispersion was incubated for
128
24 h at room temperature and then centrifuged at 10000 × g for 15 min. The obtained pellet after
129
centrifugation was separated from the supernatant and re-dispersed in de-ionized water prior to
130
further characterization.
131
2.4. Preparation of Liposome encapsulated EPI-GNPs
132
Liposomes encapsulating EPI-GNPs were formulated by the method of Rengan et al. 2014 [21].
133
Briefly, a mixture of lipids DSPC and cholesterol were dissolved in a mixture of chloroform:
134
methanol (2:1), followed by removal of chloroform and methanol using a rotary evaporator
135
(Buchi rotavap). The EPI-GNPs solution (1.0 mL) was then added to the dried cationic lipid film
136
and the mixture was incubated at room temperature for 4 h with intermittent mixing, resulting in
137
a final lipid concentration of 10 mM. To achieve a homogeneous mixture of liposomes, the
ce
pte
dM
an
us cri
pt
115
Ac
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 6 of 35
6
Page 7 of 35
suspension was sonicated for 5 min. Liposomes were annealed for 1 h at 60 °C in a water bath
139
and cooled to room temperature.
140
2.5. Determination of drug encapsulation efficiency and loading capacity
141
The EPI encapsulation and loading capacity of the formulated liposomes was measured
142
according to the method described by David et al. 2015 [22]. In short, EPI concentration in the
143
supernatant after the centrifugation of the formulated liposomes solution was detected using the
144
UV-visible spectrophotometer. The resultant supernatant was examined under UV-Visible
145
spectrophotometer which yielded an absorbance at 490 nm for EPI. Calibrated standard plots and
146
encapsulation efficiency and drug loading capacity were estimated using the absorbance values
147
and converted to quantity of EPI using the equation as given below:
148
Encapsulation efficiency (%)= (Total drug - Free drug)/Total drug × 100
149
Drug Loading capacity (%)= (Total drug - Free drug)/Nanoparticle weight × 100
150
2.6. In vitro drug release study
151
In vitro drug release characteristics of liposomes was studied by dialysis method [23]. In short,
152
free drug (EPI) was separated from liposomes (50 mg) by passing through a sephadex column of
153
dialysis bag and the dialysis bag was then immersed in beaker containing 10 mL of PBS (0.01
154
M, pH 7.4) or 10 mL of PBS (0.01 M, pH 5.0) and was subjected to separation after
155
centrifugation. After completion of experiment (as the experiment was performed in duplicate),
156
the liposomal suspension was equally divided into 10 mL and transferred to two tubes kept in a
157
shaker at 150 rpm and temperature 37 °C. Samples were withdrawn at scheduled time points,
158
the released medium was completely removed and replaced with an equal volume of fresh
159
medium. DMSO was used to dissolve the collected resultant supernatant, further the
ce
pte
dM
an
us cri
pt
138
Ac
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
AUTHOR SUBMITTED MANUSCRIPT - BPEX-101073.R1
7
AUTHOR SUBMITTED MANUSCRIPT - BPEX-101073.R1
centrifugation of this solution at 14000 × g at 25 °C ensured collection of the drugs which was
161
used for UV-visible spectrophotometric analysis.
162
%DRC = (A0 - A1) × 100/A0
163
Where, A0 = absorbance of the control; A1 = absorbance of the sample.
164
2.7. Stability studies
165
In vitro stability of EPI-GNPs encapsulated liposomes were evaluated in various physiological
166
medium (10% NaCl, 0.5% BSA) and in phosphate buffer solutions at room temperature with
167
different pH values of 1.5, 3, 5, 6, 7.4 and 9 in order to investigate pH responsive behavior of
168
liposomes. Briefly, 1 mL of EPI-GNPs encapsulated liposomes suspension was mixed with 1 mL
169
each of the physiological medium and buffer solutions and its maximum absorbance was
170
recorded after 24 h using the UV-Visible spectrophotometer.
171
2.8. Physicochemical properties of EPI-GNPs encapsulated liposomes
172
2.8.1. Fourier transform infrared spectroscopy (FTIR)
173
Infrared spectra of free EPI, EPI-GNPs and EPI-GNPs encapsulated liposomes were recorded on
174
Shimadzu IR Tracer-100, FTIR spectrophotometer. A small amount (≈1) of free EPI, EPI-GNPs
175
and EPI-GNPs encapsulated liposomes (lyophilized powder) were mixed with IR grade
176
Potassium Bromide (KBr) to prepare a round disc using a small hydraulic press to study FTIR
177
characteristic spectrum in the spectral range of 4000-400 cm-1 with resolution of 4 cm-1.
178
2.8.2. Powder X-ray Diffraction analysis
179
The purity and crystalline properties of plain EPI, EPI-GNPs and EPI-GNPs encapsulated
180
liposomes were studied by Powder XRD. The XRD scanning was done at a voltage of 20 keV
181
and a current of 30 mA with Cu Kα 1 radiation (l = 0.1542) in a two-theta (degree) configuration
182
by using A BRUKER D 8 Advance ECO XRD system with SSD160 1 D Detector.
ce
pte
dM
an
us cri
pt
160
Ac
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 8 of 35
8
Page 9 of 35
2.8.3. Particle characterization
184
The surface charge and sizes of the freshly prepared EPI-GNPs encapsulated liposomes were
185
measured by Zetasizer Nano ZS ver.7.03 (Malvern Instrument, Malvern, Worcestershire, United
186
Kingdom).
187
2.8.4. SEM analysis
188
Scanning Electron microscopic study was carried out to study and compare the morphological
189
characteristics of EPI-GNPs and EPI-GNPs encapsulated liposomes. A sample of EPI-GNPs and
190
EPI-GNPs encapsulated liposomes were placed in a 200 mesh copper grid and observed it for
191
particles shape and size using SEM detector attached to scanning electron microscopy (Carl
192
Zeiss EVO 18).
193
2.8.5. TEM analysis
194
The morphological shape and size of EPI-GNPs and EPI-GNPs encapsulated liposomes were
195
studied using transmission electron microscope (TEM-JEOL model 2100) operated at an
196
acceleration voltage of 200 KV. For this purpose, EPI-GNPs encapsulated liposomes was re-
197
dispersed with 1 mL distilled water. Few drops of dispersed nanoparticles in suspension was
198
placed on the carbon coated copper grid, which was air-dried at 60 °C for 5 min.
199
2.9. Cytotoxicity studies
200
The potential cytotoxicity of EPI-GNPs encapsulated liposomes was assessed by MTT assay
201
[24]. Shortly, breast cancer cell lines (MCF-7 cell) were seeded in to 96-multiwell plate at
202
approximately 1 × 105 cells/well at 37 °C in a 5% CO2 atmosphere for 24 h before treatment,
203
allowing for cell attachment to the wall of the plate. Cells were treated with different
204
concentrations of EPI-GNPs encapsulated liposomes (0.003, 0.006, 0.01, 0.05, 0.1, 0.2 and 0.3
205
μg/mL) for 24 h incubation. The respective amounts of DMSO in PBS buffer instead of EPI-
ce
pte
dM
an
us cri
pt
183
Ac
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
AUTHOR SUBMITTED MANUSCRIPT - BPEX-101073.R1
9
AUTHOR SUBMITTED MANUSCRIPT - BPEX-101073.R1
GNPs encapsulated liposomes was used as control. The medium was removed after 24 h of
207
treatment and cells were washed with phosphate-buffered saline (PBS, 0.01 M, pH 7.4). This
208
was followed by addition of 200 μL (5 mg/mL) of 0.5% 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-
209
diphenyl-tetrazolium bromide (MTT) prepared in serum free medium solution to each well and
210
incubated for 4 h at 37 °C in a 5% CO2. Thus, the obtained cells were fixed, washed and stained
211
with MTT. Acetic acid was used to remove excess stain while Tris-EDTA buffer was used to
212
remove any attached cells. The color intensity was measured in a microplate reader at 564 nm.
213
The ratio of the absorption of treated cells to absorption of non-treated cells expressed in
214
percentage resulted in percentage of death cells. Thus, every treatment condition was repeated in
215
triplicate and IC50 of EPI-GNPs encapsulated liposomes obtained were used for treatment for all
216
further studies.
217
2.10. Analysis of apoptotic cells by Acridine Orange/Ethidium bromide (AO/EB) double
an
us cri
staining
dM
218
pt
206
Apoptosis of the cancer cells were investigated by fluorescence microscopy after staining with
220
AO/EB [25]. Briefly, MCF-7 cancer cells were seeded on a cover slip in a 24-well plate (1×105
221
cells/well), and addition of appropriate amount of EPI-GNPs encapsulated liposomes of IC50
222
value and incubated. After being cultured for 72 h, 20 μL of trypsin was added to each well.
223
Cover slip removed from 24-well plate and washed with 1×PBS buffer and treated with dual
224
fluorescent stain 10 µL/mL containing acridine orange (10 mg/mL) and ethidium bromide (10
225
mg/mL) and incubated again 30 min. After incubation, unbound dyes were washed with 1 × PBS
226
buffer. The morphology of apoptotic cells was examined under fluorescence microscope and
227
representative fields were captured at 40× magnification. Dual AO/EB staining method was
228
repeated 3 times at least.
ce
pte
219
Ac
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 10 of 35
10
Page 11 of 35
2.11. Apoptotic analysis by Annexin V-FITC and Propidium Iodide
230
Cell apoptotic activity of EPI-GNPs encapsulated liposomes was assessed by Nouri and
231
Yazdanparast (2011) method with slight modification [26]. MCF-7 cancer cells were treated with
232
EPI-GNPs encapsulated liposomes (IC50 value) for 24 h and 48 h. After stipulated time of
233
treatment, the cells were harvested and washed twice with 1 × PBS and re-suspended in 100 µL
234
binding buffer (10 mM HEPES/NaOH of pH 7.4, 140 mM NaCl and 2.5 mM CaCl2). Next,
235
Annexin V-FITC (10 µL) was added to the cells followed by the addition of 10 µL of PI (50
236
µg/mL in PBS). The samples were incubated for 10 min in the dark at 4 °C and then analyzed by
237
flow cytometry.
238
2.12. ROS generation assay
239
Intracellular ROS generation in control and treated MCF-7 cancer cells were monitored by
240
measuring changes in fluorescence resulting from intracellular probe oxidation [27]. The cancer
241
cells seeded in 6-well culture plate (1×105 cells/well) and incubated for 24h. After incubation,
242
the medium was replaced with 10% FBS supplemented with IC50 value of EPI-GNPs
243
encapsulated liposomes, and again incubated for 24 and 48 h. The cells were washed twice with
244
1× PBS and 20 μM DCFH-DA was added and incubated for another 10 min. The DCFH-DA was
245
removed, and then 100 μM H2O2 was added into the cells and incubated for 45 min. The change
246
in the fluorescence was monitored by fluorescence spectrophotometer at λex=475 nm, λem=525
247
nm.
248
2.13. Statistical analysis
249
Experiments for each sample were performed three times, and obtained values were presented as
250
mean ± standard deviation (SD). Data were analyzed by one-way analysis of variance (ANOVA)
251
and Student-t test. A value of p